Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 2:ciab930. doi: 10.1093/cid/ciab930

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 1. — Anti–severe acute respiratory syndrome coronavirus 2 antibody results for allogeneic hematopoietic stem cell transplant (HSCT) recipients and healthy participants. A–D, Simoa assay titers for anti-N immunoglobulin (Ig) G (A), anti-S IgG (B), anti-S1 IgG (C), and anti–receptor-binding domain (RBD) IgG. E, F, Roche assay results for anti-N (E) and anti-S (F) total immunoglobulin (Ig) values at baseline (before vaccination), at dose 2, and 28 days after completion of the vaccine series. Thick horizontal bars and error lines represent medians and interquartile ranges, respectively, and dotted lines represent cutoff thresholds for each assay (Simoa assay: 1.07 normalized average enzymes per bead [AEB] for anti-S IgG and 5.2 normalized AEB for anti-N IgG [no thresholds determined for anti-RBD or anti-S1]; Roche assay: 0.8 U/mL for anti-S and 1.0 cutoff index [COI] for anti-N total immunoglobulin). All participants in the allogeneic HSCT and healthy cohorts had negative anti-N IgG (A) and anti-N total immunoglobulin (E) results throughout the study. P values represent comparisons between the allogeneic HSCT and healthy cohorts at dose 2 and 28 days after series completion. All temporal values within the allogeneic HSCT or healthy cohort for anti-S, anti-S1, and anti-RBD (Simoa) and anti-S (Roche) represent significant differences (P < .001), indicating a significant rise in antibody magnitude from baseline to the time of dose 2, and from dose 2 to 28 days after series completion.